A phase 3, open-label, multicenter, randomized study to investigate the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus docetaxel in patients with non-small cell lung cancer who have progressed on a prior platinum-containing regimen.

Dingzhi Huang,Ziping Wang,Xinmin Yu,Ying Cheng,Jie Wang,Yun Fan,Zhiyong Ma,Jianhua Shi,Yan Yu,Yi Hu,James Song,Fan Xia,Zhirong Shen,Yun Zhang,Yingying Xu,Carrie Condon,Fangniu Shi,Yunfei Zhou,Andrea Pirzkall,Caicun Zhou

A phase 3, open-label, multicenter, randomized study to investigate the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus docetaxel in patients with non-small cell lung cancer who have progressed on a prior platinum-containing regimen.

2018

TPS3112Background: Non-small cell lung cancer (NSCLC) accounts for 80–85% of all lung cancers and has a poor prognosis in later stages. Although lung cancers are not typically immunogenic, recent s...

Keywords:

Physical therapy
Antibody
Regimen
Randomized controlled trial
Cancer research
Lung cancer
Medicine
Docetaxel
Oncology
in patient
non small cell
Internal medicine
anti pd 1
Lung
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations